Dynavax Technologies (NASDAQ:DVAX) Upgraded to “Buy” at StockNews.com

Dynavax Technologies (NASDAQ:DVAX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

DVAX has been the topic of a number of other reports. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock traded up $0.09 on Monday, hitting $13.42. The stock had a trading volume of 2,026,956 shares, compared to its average volume of 1,843,953. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 74.56 and a beta of 1.32. The business’s 50 day moving average is $12.83 and its two-hundred day moving average is $12.06. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.05.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Analysts forecast that Dynavax Technologies will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. E Fund Management Co. Ltd. increased its holdings in Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 771 shares during the period. Summit Investment Advisors Inc. boosted its position in shares of Dynavax Technologies by 7.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 904 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC raised its position in Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,169 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.